Detection and measurement of clinically meaningful visual field progression in clinical trials for glaucoma
Open accessThe DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
Abstract
Glaucomatous visual field progression has both personal and societal costs and therefore has a serious impact on quality of life. At the present time, intraocular pressure (IOP) is considered to be the most important modifiable risk factor for glaucoma onset and progression. Reduction of IOP has been repeatedly demonstrated to be an effective intervention across the spectrum of glaucoma, regardless of subtype or disease stage. In the setting of approval of IOP‐lowering therapies, it is expected that effects on IOP will translate into benefits in long‐term patient‐reported outcomes. Nonetheless, the effect of these medications on IOP and their associated risks can be consistently and objectively measured. This helps to explain why regulatory approval of new therapies in glaucoma has historically used IOP as the outcome variable. Although all approved treatments for glaucoma involve IOP reduction, patients frequently continue to progress despite treatment. It would therefore be beneficial to develop treatments that preserve visual function through mechanisms other than lowering IOP. The United States Food and Drug Administration (FDA) has stated that they will accept a clinically meaningful definition of visual field progression using Glaucoma Change Probability criteria. Nonetheless, these criteria do not take into account the time (and hence, the speed) needed to reach significant change. In this paper we provide an analysis based on the existing literature to support the hypothesis that decreasing the rate of visual field progression by 30% in a trial lasting 12–18 months is clinically meaningful. We demonstrate that a 30% decrease in rate of visual field progression can be reliably projected to have a significant effect on health‐related quality of life, as defined by validated instruments designed to measure that endpoint. HIGHLIGHTSA 30% decrease in rate of visual field progression can be projected to have a significant effect on health‐related quality of life.The US FDA definition of clinically‐meaningful progression corresponds to a slope ≤−0.5 dB/yr in ≥5 abnormal test locations.A 30% decrease in visual field progression with trend analysis is equivalent to a 2–3 mmHg decrease in intraocular pressure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The number of people with glaucoma worldwide in 2010 and 2020
Quigley, H. A. (2006) · British Journal of Ophthalmology · doi:10.1136/bjo.2005.081224 · Cited by 7,394 · cited 1×
“…A 2006 review of worldwide glaucoma prevalence models estimated that by 2010 glaucoma would be the second leading overall cause of blindness in the world and leading cause of irreversible blindness, affecting 60.5 million people with prevalence varying worldwide(Quigley and Broman, 2006) (Error!”
InfluentialGlobal data on visual impairment in the year 2002.
(2004) · Europe PMC (PubMed Central) · Cited by 4,157
Kass, M. A. (2002) · Archives of Ophthalmology · doi:10.1001/archopht.120.6.701 · Cited by 3,705 · cited 10×
“The Ocular Hypertension Treatment Study (OHTS) compared the effects of IOP-lowering therapy on the risk of OAG development among subjects with statistically high IOP despite normal visual field results and optic nerve head evaluation(Gordon et al., 2002).”
InfluentialHeijl, A. (2002) · Archives of Ophthalmology · doi:10.1001/archopht.120.10.1268 · Cited by 3,320 · cited 19×
“The Early Manifest Glaucoma Trial (EMGT) randomized patients with newly diagnosed glaucoma to treatment and observation arms, confirming the important effect of baseline IOP levels and IOPlowering on progression(Leske et al., 2007).”
InfluentialNumber of people with glaucoma worldwide.
Quigley, H. A. (1996) · British Journal of Ophthalmology · doi:10.1136/bjo.80.5.389 · Cited by 2,998 · cited 2×
“(Quigley, 1996) A 2006 review of worldwide glaucoma prevalence models estimated that by 2010 glaucoma would be the second leading overall cause of blindness in the world and leading cause of irreversible blindness, affecting 60.5 million people with prevalence varying worldwide(Quigley and Broman,…”
Influential(2000) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(00)00538-9 · Cited by 2,780
Gordon, M. O. (2002) · Archives of Ophthalmology · doi:10.1001/archopht.120.6.714 · Cited by 2,626
Social Indicators of Well-Being: Americans' Perceptions of Life Quality
Andrews, F. M., & Withey, S. B. (1976) · Medical Entomology and Zoology · Cited by 2,409
Factors for Glaucoma Progression and the Effect of Treatment: The Early Manifest Glaucoma Trial
Leske, M. C. (2003) · Archives of Ophthalmology · doi:10.1001/archopht.121.1.48 · Cited by 2,030
(1998) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(98)00223-2 · Cited by 1,599
WHOQOL Group (1993) · Quality of Life Research · doi:10.1007/bf00435734 · Cited by 1,375
Predictors of Long-term Progression in the Early Manifest Glaucoma Trial
Leske, M. C., Heijl, A., Hyman, L., Bengtsson, B., Dong, L., & Yang, Z. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.03.016 · Cited by 1,363 · cited 5×
“The Early Manifest Glaucoma Trial (EMGT) randomized patients with newly diagnosed glaucoma to treatment and observation arms, confirming the important effect of baseline IOP levels and IOPlowering on progression(Leske et al., 2007).”
InfluentialThe effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma
(1998) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(98)00272-4 · Cited by 1,301
Lichter, P. (2001) · Ophthalmology · doi:10.1016/s0161-6420(01)00873-9 · Cited by 1,178 · cited 13×
“…resulted in a 0.36 unit worse visual field score than initial medical treatment (P = 0.03); however, when the influence of cataract extraction on visual field data was included in the model, the difference decreased to 0.28 units and was only marginally significant (P = 0.07)(Lichter et al., 2001).”
InfluentialPrevalence of Open-Angle Glaucoma Among Adults in the United States
(2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.4.532 · Cited by 1,110 · cited 1×
“)(Friedman et al., 2004).”
Peripheral vision and pattern recognition: A review
Strasburger, H., Rentschler, I., & Jüttner, M. (2011) · Journal of Vision · doi:10.1167/11.5.13 · Cited by 943 · cited 1×
“It has now been well-established that most visual functions decline with age both for the fovea and the periphery(Strasburger et al., 2011), and it is common practice to take this into account when assessing function in pathologic eyes, particularly in cases of glaucomatous loss.”
Glaucomatous damage of the macula
Hood, D. C., Raza, A. S., de Moraes, C. G. V., Liebmann, J. M., & Ritch, R. (2013) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2012.08.003 · Cited by 867 · cited 1×
“While it is clear that early, even initial, glaucomatous damage can involve these RGCs and the macula(Hood et al., 2013; Hood et al., 2014), the nature of this damage is incompletely understood.”
Self-citationRisk factors for progression of visual field abnormalities in normal-tension glaucoma
Drance, S., Anderson, D. R., & Schulzer, M. (2001) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(01)00964-3 · Cited by 790 · cited 1×
“However, lowering of IOP does not halt all cases of progression(AAO, 2010; De Moraes et al., 2012b; Drance et al., 2001; Gordon et al., 2002; Leske et al., 2007; Musch et al., 2009).”
Nouri-Mahdavi, K., Hoffman, D., Coleman, A. L., Liu, G., Li, G., Gaasterland, D., & Caprioli, J. (2004) · Ophthalmology · doi:10.1016/j.ophtha.2004.02.017 · Cited by 704 · cited 3×
“On the other hand, the AGIS showed that patients with better baseline MD values were at increased risk of progression(Nouri-Mahdavi et al., 2004a), most likely because the majority of patients had severe visual fields at baseline which precluded the detection of change due to the “floor effect.””
InfluentialA framework for comparing structural and functional measures of glaucomatous damage
Hood, D. C., & Kardon, R. H. (2007) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2007.08.001 · Cited by 703 · cited 1×
“function model, visual field sensitivity measured in linear scale (1/L) has a linear relationship with retinal nerve fiber layer (RNFL) thickness measured with OCT.(Hood and Kardon, 2007) Therefore, the rates of progression measured with 1/L/year also show a linear relationship with the rates of RNFL loss/year in glau…”
Terminology and guidelines for glaucoma
Molina-Castañer, S. (2009) · Hispana · Cited by 665
Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial
Garway-Heath, D. F., Crabb, D. P., Bunce, C., Lascaratos, G., Amalfitano, F., Anand, N., Azuara-Blanco, A., Bourne, R. R., Broadway, D. C., Cunliffe, I. A., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62111-5 · Cited by 660 · cited 6×
“26 3.5.5 Low-pressure Glaucoma Treatment Study (LoGTS) ....................................................... 26 3.5.6 United Kingdom Glaucoma Treatment Study (UKGTS) .................................................. 28 M AN US CR IP T AC CE PT ED ACCEPTED MANUSCRIPT 3 Large Cohort Studies and Glaucoma Progression .…”
InfluentialMeasurement of quality of life: current state of the art.
Flanagan, J. C. (1982) · PubMed · Cited by 610
Practical recommendations for measuring rates of visual field change in glaucoma
Chauhan, B. C., Garway-Heath, D. F., Goni, F. J., Rossetti, L., Bengtsson, B., Viswanathan, A. C., & Heijl, A. (2008) · British Journal of Ophthalmology · doi:10.1136/bjo.2007.135012 · Cited by 530
A Population-based Evaluation of Glaucoma Screening: The Baltimore Eye Survey
Tielsch, J. M., Katz, J., Singh, K., Quigley, H. A., Gottsch, J. D., Javitt, J., & Sommer, A. (1991) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a116013 · Cited by 484 · cited 1×
“In addition, failure to test the visual field can miss up to one third of those with the disease(Tielsch et al., 1991).”
Normal Variability of Static Perimetric Threshold Values Across the Central Visual Field
Heijl, A., Lindgren, G., & Olsson, J. (1987) · Archives of Ophthalmology · doi:10.1001/archopht.1987.01060110090039 · Cited by 442 · cited 2×
“7 dB per decade and greater peripherally than centrally(Heijl et al., 1987).”
InfluentialVisual Field Progression in the Collaborative Initial Glaucoma Treatment Study
Musch, D. C., Gillespie, B. W., Lichter, P. R., Niziol, L. M., & Janz, N. K. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2008.08.051 · Cited by 439 · cited 5×
“…greater cup-to-disc ratio, decreased central corneal thickness (CCT), older age, pseudoexfoliation syndrome, genetic factors, and ocular perfusion pressure(AGIS, 2002; De Moraes et al., 2012b; Gordon et al., 2002; Leske et al., 2007; Lichter et al., 2001; Miglior et al., 2005; Musch et al., 2009).”
InfluentialClinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents, 2005-2012
Downing, N. S., Aminawung, J. A., Shah, N. D., Krumholz, H. M., & Ross, J. S. (2014) · JAMA · doi:10.1001/jama.2013.282034 · Cited by 407 · cited 1×
“A recent study aimed to characterize pivotal efficacy trials for newly approved novel therapeutic agents between 2005 and 2012, showed that although patient-reported clinical outcomes and scales were used in many pivotal trials, trials with surrogate endpoints as their primary outcome formed the exclusive basis of app…”
Influence of Glaucomatous Visual Field Loss on Health-Related Quality of Life
Gutierrez, P. (1997) · Archives of Ophthalmology · doi:10.1001/archopht.1997.01100150779014 · Cited by 400 · cited 3×
“(Andrews and Withey, 1976; Flanagan, 1982) This concept of quality of life was later utilized in the assessment of chronically ill patients, including those with mental illness, cancer, and cardiovascular disease, and in the elderly, including glaucoma patients(Flanagan, 1982; Gutierrez et al., 1997; Parrish, 1996).”
Natural History of Open-Angle Glaucoma
Heijl, A., Bengtsson, B., Hyman, L., & Leske, M. C. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2009.06.042 · Cited by 394 · cited 3×
“Assuming a linear relationship, this translates to a treatment effect of 2-3 mm Hg to decelerate the rate of MD progression by 30%(Heijl et al., 2009) (see also the 3 points in the Introduction).”
Quality of Life in Glaucoma and Its Relationship with Visual Function
Nelson, P., Aspinall, P., Papasouliotis, O., Worton, B., & O'Brien, C. (2003) · Journal of Glaucoma · doi:10.1097/00061198-200304000-00009 · Cited by 387 · cited 1×
“Glaucoma impacts patient HRQOL in multiple ways, including driving, walking, and reading(Gutierrez et al., 1997; Haymes et al., 2007; Nelson et al., 2003).”
Risk Factors for Visual Field Progression in Treated Glaucoma
De Moraes, C. G. V. (2010) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2011.72 · Cited by 356 · cited 1×
“We performed a similar analysis with the NY-GAPS database by investigating the rate of progression of abnormal locations at baseline as compare with the global MD rate(De Moraes et al., 2011).”
Self-citation(2007) · Ophthalmology · doi:10.1016/j.ophtha.2006.08.031 · Cited by 351 · cited 2×
“Therefore, some of the strategies to improve the viability of future RCTs testing neuroprotective agents, without resorting to larger sample sizes and longer follow-up periods, are to (i) select patients at high-risk risk of progression at baseline (for example, based on risk calculators)(De Moraes et al., 2012c; Gord…”
Expert Agreement in Evaluating the Optic Disc for Glaucoma
Varma, R., Steinmann, W. C., & Scott, I. U. (1992) · Ophthalmology · doi:10.1016/s0161-6420(92)31990-6 · Cited by 330 · cited 1×
“Disc examination alone is not adequately specific, and studies that use “expert” subjective assessment of disc and field may lack reproducibility(Tielsch et al., 1988; Varma et al., 1992).”
The probability of blindness from open-angle glaucoma
Hattenhauer, M. G., Johnson, D. H., Ing, H. H., Herman, D. C., Hodge, D. O., Yawn, B. P., Butterfield, L. C., & Gray, D. T. (1998) · Ophthalmology · doi:10.1016/s0161-6420(98)91133-2 · Cited by 326 · cited 9×
“Perhaps the most important factor in assessing visual compromise is that of functional visual constraints in the context of activities of daily living(Hattenhauer et al., 1998).”
InfluentialThe Glaucoma Laser Trial (GLT) and Glaucoma Laser Trial Follow-up Study: 7. Results
(1995) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(14)72725-4 · Cited by 324
Results of the European Glaucoma Prevention Study
(2005) · Ophthalmology · doi:10.1016/j.ophtha.2004.11.030 · Cited by 323 · cited 2×
“…greater cup-to-disc ratio, decreased central corneal thickness (CCT), older age, pseudoexfoliation syndrome, genetic factors, and ocular perfusion pressure(AGIS, 2002; De Moraes et al., 2012b; Gordon et al., 2002; Leske et al., 2007; Lichter et al., 2001; Miglior et al., 2005; Musch et al., 2009).”
Changing views on open-angle glaucoma: definitions and prevalences--The Rotterdam Study.
Wolfs, R. C. W., Borger, P. H., Ramrattan, R. S., Klaver, C. C. W., Hulsman, C. A. A., Hofman, A., Vingerling, J. R., Hitchings, R. A., & de Jong, P. T. V. M. (2000) · PubMed · Cited by 321
Biomarkers and surrogate endpoints
Aronson, J. K. (2005) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02435.x · Cited by 312
Risk of Falls and Motor Vehicle Collisions in Glaucoma
Haymes, S. A., LeBlanc, R. P., Nicolela, M. T., Chiasson, L. A., & Chauhan, B. C. (2007) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.06-0886 · Cited by 311 · cited 1×
“Glaucoma impacts patient HRQOL in multiple ways, including driving, walking, and reading(Gutierrez et al., 1997; Haymes et al., 2007; Nelson et al., 2003).”
Intraobserver and Interobserver Agreement in Measurement of Optic Disc Characteristics
Tielsch, J. M., Katz, J., Quigley, H. A., Miller, N. R., & Sommer, A. (1988) · Ophthalmology · doi:10.1016/s0161-6420(88)33177-5 · Cited by 274 · cited 1×
“Disc examination alone is not adequately specific, and studies that use “expert” subjective assessment of disc and field may lack reproducibility(Tielsch et al., 1988; Varma et al., 1992).”
Severity of Visual Field Loss and Health-related Quality of Life
McKean-Cowdin, R., Varma, R., Wu, J., Hays, R. D., & Azen, S. P. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.02.022 · Cited by 260 · cited 3×
“In the Los Angeles Latino Eye Survey (LALES)(McKean-Cowdin et al., 2007), the relationship between the NEI-VFQ-25 and MD of the better- or worse-seeing eye was investigated.”
Ocular Surface Disease and Quality of Life in Patients With Glaucoma
Skalicky, S. E., Goldberg, I., & McCluskey, P. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2011.05.033 · Cited by 254
(2002) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(02)01659-8 · Cited by 233
Assessment of the Reliability of Standard Automated Perimetry in Regions of Glaucomatous Damage
Gardiner, S. K., Swanson, W. H., Goren, D., Mansberger, S. L., & Demirel, S. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.01.020 · Cited by 212 · cited 2×
“Gardiner et al investigated the lower limit of the effective dynamic range of SAP beyond which reliable measures of sensitivity cannot be obtained(Gardiner et al., 2014).”
Risk assessment in the management of patients with ocular hypertension
Weinreb, R. N., Friedman, D. S., Fechtner, R. D., Cioffi, G. A., Coleman, A. L., Girkin, C. A., Liebmann, J. M., Singh, K., Wilson, M. R., Wilson, R., et al. (2004) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2004.04.054 · Cited by 204 · cited 1×
“Weinreb et al described the first attempt to reach that aim with the available data and several assumptions regarding disease progression to model the risk of blindness in patients with ocular hypertension(Weinreb et al., 2004).”
Self-citationPark, S. C., Moraes, C. G. D., Teng, C. C., Tello, C. A., Liebmann, J. M., & Ritch, R. H. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2011.02.013 · Cited by 200 · cited 1×
“Park et al(Park et al., 2011) compared clinical characteristics between patients with initial paracentral defects with those with peripheral nasal defects.”
Self-citationLifetime Risk of Blindness in Open-Angle Glaucoma
Peters, D., Bengtsson, B., & Heijl, A. (2013) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2013.05.027 · Cited by 198 · cited 8×
“The United States Food and Drug Administration (FDA) has stated that they will accept a clinically meaningful definition of visual field progression using Glaucoma Change Probability criteria.”
InfluentialSkalicky, S., & Goldberg, I. (2008) · Journal of Glaucoma · doi:10.1097/ijg.0b013e318163bdd1 · Cited by 190 · cited 1×
“02).(Skalicky and Goldberg, 2008) Summary and sub-factor scores of HRQOL instruments reflected decreased QOL with increased glaucoma severity.”
Oliver, J. E., Hattenhauer, M. G., Herman, D., Hodge, D. O., Kennedy, R., Fang-Yen, M., & Johnson, D. H. (2002) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(02)01403-4 · Cited by 181 · cited 1×
“, 1998) and Oliver et al (Oliver et al., 2002) (Olmsted) 295; retrospective 3 groups treated pts;(1) 114 OAG (2 of 3 criteria: IOP ≥21, ON or VF defects);(2) 177 ocular hypertension (treated IOP ≥21);(3) 4 undocumented OAG Legal blindness 15 years ± 8 years 9% overall probability of bilateral blindness at 20 years (4%…”
Delaying Treatment of Ocular Hypertension: The Ocular Hypertension Treatment Study
(2010) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2010.20 · Cited by 172 · cited 1×
“)(Kass et al., 2010).”
Treatment and Vision-Related Quality of Life in the Early Manifest Glaucoma Trial
Hyman, L. G., Komaroff, E., Heijl, A., Bengtsson, B., & Leske, M. C. (2005) · Ophthalmology · doi:10.1016/j.ophtha.2005.03.028 · Cited by 164 · cited 1×
“More importantly, the study showed that visual function as measured by SAP affected vision-targeted QOL up to six years after study enrollment, as measured with HRQOL questionnaires throughout the trial(Hyman et al., 2005).”
Hood, D. C., Slobodnick, A., Raza, A. S., de Moraes, C. G., Teng, C. C., & Ritch, R. (2014) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.13-13130 · Cited by 162 · cited 3×
“Over 30% of the RGCs are within the macular region(Hood et al., 2014), which is often defined as the central 8° of the visual field.”
InfluentialSelf-citationFear of Falling and Visual Field Loss from Glaucoma
Ramulu, P. Y., van Landingham, S. W., Massof, R. W., Chan, E. S., Ferrucci, L., & Friedman, D. S. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.01.037 · Cited by 156 · cited 1×
“58 To determine if visual field loss resulting from glaucoma is associated with greater fear of falling, investigators designed a prospective, observational study which recruited 143 subjects (83 glaucoma subjects with bilateral visual field loss and 60 control subjects with good VA and no significant visual field los…”
Heijl, A., Bengtsson, B., Chauhan, B. C., Lieberman, M. F., Cunliffe, I. A., Hyman, L., & Leske, M. C. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2008.02.005 · Cited by 155 · cited 13×
“The Early Manifest Glaucoma Trial (EMGT) randomized patients with newly diagnosed glaucoma to treatment and observation arms, confirming the important effect of baseline IOP levels and IOPlowering on progression(Leske et al., 2007).”
InfluentialEuropean Glaucoma Prevention Study: Author reply
Miglior, S., Pfeiffer, N., Zeyen, T. G., Cunha-Vaz, J. G., Torri, V., & Adamsons, I. A. (2005) · Ophthalmology · doi:10.1016/j.ophtha.2005.06.020 · Cited by 153 · cited 2×
“…greater cup-to-disc ratio, decreased central corneal thickness (CCT), older age, pseudoexfoliation syndrome, genetic factors, and ocular perfusion pressure(AGIS, 2002; De Moraes et al., 2012b; Gordon et al., 2002; Leske et al., 2007; Lichter et al., 2001; Miglior et al., 2005; Musch et al., 2009).”
Factors associated with lifetime risk of open‐angle glaucoma blindness
Peters, D., Bengtsson, B., & Heijl, A. (2014) · Acta Ophthalmologica · doi:10.1111/aos.12203 · Cited by 148 · cited 8×
“The United States Food and Drug Administration (FDA) has stated that they will accept a clinically meaningful definition of visual field progression using Glaucoma Change Probability criteria.”
InfluentialWall, M., Woodward, K. R., Doyle, C. K., & Artes, P. H. (2009) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.08-1789 · Cited by 148
Risk Factors for Visual Field Progression in the Low-pressure Glaucoma Treatment Study
Moraes, C. G. D., Liebmann, J. M., Greenfield, D. S., et al. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2012.04.015 · Cited by 136 · cited 6×
“…greater cup-to-disc ratio, decreased central corneal thickness (CCT), older age, pseudoexfoliation syndrome, genetic factors, and ocular perfusion pressure(AGIS, 2002; De Moraes et al., 2012b; Gordon et al., 2002; Leske et al., 2007; Lichter et al., 2001; Miglior et al., 2005; Musch et al., 2009).”
InfluentialSelf-citationImportance of Visual Acuity and Contrast Sensitivity in Patients With Glaucoma
Richman, J. (2010) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2010.275 · Cited by 136 · cited 1×
“The study enrolled 192 glaucoma patients with a full range of glaucomatous visual loss that were selected from the Glaucoma Service of Wills Eye Institute(Richman et al., 2010).”
Age-related changes in the central visual field for short-wavelength-sensitive pathways
Johnson, C. A., Adams, A. J., Twelker, J. D., & Quigg, J. M. (1988) · Journal of the Optical Society of America A · doi:10.1364/josaa.5.002131 · Cited by 132 · cited 1×
“Johnson et al found that the reduction in sensitivity of short wavelength-sensitive cone pathways (such as those stimulated in SWAP) resulting from aging was greater than that for longer wavelength-sensitive cone pathways(Johnson et al., 1988).”
Patient-Reported Outcome Measures in Safety Event Reporting: PROSPER Consortium Guidance
Banerjee, A. K., Okun, S., Edwards, I. R., Wicks, P. J., Smith, M. Y., Mayall, S. J., Flamion, B., Cleeland, C. S., & Basch, E. (2013) · Drug Safety · doi:10.1007/s40264-013-0113-z · Cited by 125
Identifying Areas of the Visual Field Important for Quality of Life in Patients with Glaucoma
Murata, H., Hirasawa, H., Aoyama, Y., Sugisaki, K., Araie, M., Mayama, C., Aihara, M., & Asaoka, R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058695 · Cited by 117 · cited 2×
“59 One study aimed to create a vision-related QOL prediction system to identify visual field test points associated with decreased vision-related QOL in patients with glaucoma(Murata et al., 2013).”
Weinreb, R. N., & Kaufman, P. L. (2009) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.08-2843 · Cited by 116 · cited 7×
“QOL measures provide very useful supportive information, and the FDA encourages their use in clinical trials.(Weinreb and Kaufman, 2009) Whether these measures end up in the product label depends on proper administration of the instrument, proper validation, and adequate statistical power to show differences between s…”
InfluentialVariability in patients with glaucomatous visual field damage is reduced using size V stimuli.
Wall, M., Kutzko, K. E., & Chauhan, B. C. (1997) · PubMed · Cited by 114
Kymes, S. M., Kass, M. A., Anderson, D. R., Miller, J. P., & Gordon, M. O. (2006) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2006.01.019 · Cited by 107 · cited 1×
“Similarly, Kymes et al(Kymes et al., 2006) concluded that treating individuals with an IOP of 24 mm Hg and who had ≥ 2% annual risk of developing glaucoma met cost-effectiveness standards accepted in most developed countries.”
Lisboa, R. D. D. R., Chun, Y. S., Zangwill, L. M., Weinreb, R. N., Rosen, P. N., Liebmann, J. M., Girkin, C. A., & Medeiros, F. A. (2013) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2013.2602 · Cited by 101 · cited 1×
“worse vision-related quality of life (VRQOL) than the patient with slowly progressing damage(Lisboa et al., 2013).”
Self-citationVisual Field Progression Differences between Normal-Tension and Exfoliative High-Tension Glaucoma
Ahrlich, K., Moraes, C. G. V. D., Teng, C. C., Prata, T. S., Tello, C. A., Ritch, R. H., & Liebmann, J. M. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.09-3806 · Cited by 99 · cited 1×
“Baseline central visual loss (within the central four points on the 24-2 VF) occurred more frequently in low-pressure glaucoma patients (58.9% versus 31.8% of eyes, P 0.01)(Ahrlich et al., 2010).”
InfluentialSelf-citationRein, D. B., Wittenborn, J. S., Lee, P. P., Wirth, K. E., Sorensen, S. W., Hoerger, T. J., & SAADDINE, J. B. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2008.12.056 · Cited by 85
Zhu, H., Russell, R. A., Saunders, L. J., Ceccon, S., Garway‐Heath, D. F., & Crabb, D. P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085654 · Cited by 80 · cited 3×
“, 2007) (ii) and employing trend-based visual field progression criteria, particularly those that employ methods to overcome the increase of variability with progression(Zhu et al., 2014) and that censor severe defects(Gardiner et al.”
InfluentialVisual impairment, visual functioning, and quality of life assessments in patients with glaucoma
Parrish, R. K. (1997) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(14)70205-3 · Cited by 79 · cited 4×
“A separate study tested whether another global visual field index, the PSD, also correlates with instruments measuring HRQOL.(Parrish, 1996) Seventy-seven patients with glaucoma were”
InfluentialClinical trials for glaucoma neuroprotection are not impossible
Quigley, H. A. (2012) · Current Opinion in Ophthalmology · doi:10.1097/icu.0b013e32834ff490 · Cited by 76 · cited 1×
“Quigley also addressed the challenges of designing RCTs for glaucoma neuroprotection and provided additional recommendations to improve their design(Quigley, 2012).”
Gardiner, S. K., Swanson, W. H., & Demirel, S. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.15-18000 · Cited by 69 · cited 2×
“They concluded that restricting the range of contrast used in clinical perimetry may be possible without hampering the ability to monitor glaucomatous visual field progression(Gardiner et al., 2016).”
Assessment of the Vision-specific Quality of Life Using Clustered Visual Field in Glaucoma Patients
Sawada, H., Yoshino, T., Fukuchi, T., & Abe, H. (2012) · Journal of Glaucoma · doi:10.1097/ijg.0b013e318265bbdc · Cited by 69
Robust and Censored Modeling and Prediction of Progression in Glaucomatous Visual Fields
Bryan, S. R., Vermeer, K. A., Eilers, P. H. C., Lemij, H. G., & Lesaffre, E. M. E. H. (2013) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.12-11185 · Cited by 66 · cited 2×
“Given that classic regression with least square estimates is based on certain assumptions that conflict with visual field data, another study investigated different regression models and their assumptions in order to determine pointwise visual field progression in glaucoma and to better predict future visual field los…”
Rao, H. L., Kumar, A. U., Jonnadula, G. B., Senthil, S., & Garudadri, C. S. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2010.05.027 · Cited by 63 · cited 1×
“The relationship between severity of visual field loss at presentation and rate of visual field loss progression in glaucoma was studied(Rao et al., 2011).”
Cost-effectiveness of Treating Ocular Hypertension
Stewart, W. C., Stewart, J. A., Nassar, Q. J., & Mychaskiw, M. A. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2007.01.040 · Cited by 62 · cited 2×
“In another study, Stewart et al(Stewart et al., 2008) developed a model to evaluate the long-term cost-effectiveness of treating ocular hypertension in the US to prevent progression to glaucoma.”
Statistical aspects of the normal visual field in short-wavelength automated perimetry.
Wild, J. M., Cubbidge, R. P., Pacey, I. E., & Robinson, R. J. (1998) · PubMed · Cited by 62
The Effect of Stimulus Size on the Reliable Stimulus Range of Perimetry
Gardiner, S. K., Demirel, S., Goren, D., Mansberger, S. L., & Swanson, W. H. (2015) · Translational Vision Science & Technology · doi:10.1167/tvst.4.2.10 · Cited by 48 · cited 1×
“In another study the investigators found no evidence that use of a size V stimulus significantly decreased the lower limit of the reliable stimulus range beyond 15 to 19 dB(Gardiner et al., 2015);”
Moraes, C. G. D., Sehi, M., Greenfield, D. S., Chung, Y. S., Ritch, R. H., & Liebmann, J. M. (2012) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.11-7900 · Cited by 46 · cited 6×
“…greater cup-to-disc ratio, decreased central corneal thickness (CCT), older age, pseudoexfoliation syndrome, genetic factors, and ocular perfusion pressure(AGIS, 2002; De Moraes et al., 2012b; Gordon et al., 2002; Leske et al., 2007; Lichter et al., 2001; Miglior et al., 2005; Musch et al., 2009).”
InfluentialSelf-citationOutcomes in Registered, Ongoing Randomized Controlled Trials of Patient Education
Pino, C. V. D. C. D., Boutron, I., & Ravaud, P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042934 · Cited by 29 · cited 1×
“On the other hand, “surrogate outcomes” are defined as “a characteristic intended to substitute for a clinical endpoint”(NIH, 2000; Pino et al., 2012).”
Signal/Noise Analysis to Compare Tests for Measuring Visual Field Loss and Its Progression
Artes, P. H., & Chauhan, B. C. (2009) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.09-3601 · Cited by 20 · cited 1×
“This applies to the detection of abnormalities with single examinations as well as to the measurement of change over time with serial examinations.(Artes and Chauhan, 2009)”
Cited by
Neuroprotection in Glaucoma: Animal Models and Clinical Trials
Almasieh, M., & Levin, L. A. (2017) · Annual Review of Vision Science · doi:10.1146/annurev-vision-102016-061422 · Cited by 111
Self-citation
Metadata
- Authors
- De Moraes, C. G., Liebmann, J. M., & Levin, L. A.
- Venue
- Progress in Retinal and Eye Research
- Publisher
- Elsevier BV
- Published
- 2017-01
- Volume
- 56
- Pages
- 107-147
- ISSN
- 1350-9462 (ISSN-L)
- OpenAlex
- W2538869024
- Cited by
- 203
- References
- 82
- FWCI
- 10.80
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.